Weight loss jabs are transforming obesity treatment, but without access to affordable healthy food and ongoing support they could widen health inequalities in the UK, experts have warned.
The injections, also known as GLP-1 receptor agonists, are taken by an estimated 2.4 million Britons and work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
Although drugs such as Wegovy and Mounjaro have transformed weight-loss treatment, researchers at Cambridge University and University College London (UCL) have argued that their long-term benefits depend on diet, exercise and healthcare support.
“We have highlighted that obesity treatment is not just a medical issue, but a social and structural one. Without integrated dietary support and attention to food affordability, these medications could deepen existing health inequalities,” Dr Adrian Brown at UCL Medicine said.
“The key message is clear: these treatments are powerful, but their long-term public health impact will depend on whether the right support systems are in place to ensure equitable and safe access for all patients,” he added.
The report, published in the journal Nature Medicine, warned that healthier diets are often more expensive, and on top of the cost of weight-loss jabs, are unaffordable for many.
Dr Marie Spreckley from Cambridge University said: “The key question is not simply who can access these medications, but who can benefit from them in the long term. If access to healthy food, nutrition support and ongoing care is uneven, there is a risk that the benefits of these treatments will also be uneven.”
Source: The Independent, 1 June 2026
Recommended Comments
Create an account or sign in to comment